Dr. Ward on Multigene Testing in Breast Cancer

John H. Ward, MD
Published: Friday, Mar 22, 2019



John H. Ward, MD, professor of Medicine, Huntsman Cancer Institute, University of Utah, discusses his preferences in multilane testing for patients with hormone receptor (HR)–positive, node-negative breast cancer.

For patients with HR-positive, node-negative breast cancer who would be considered for chemotherapy, the current recommendation is the 21-gene recurrence score as it is believed to be predictive of chemotherapy benefit. However, there are a couple of caveats, Ward explains. First, if a patient has already been tested with other assays, it is unnecessary to repeat testing with the 21-gene recurrence score. 

Ward says that there is no wrong choice when it comes to selecting an assay, but the 21-gene recurrence score is his preference. For patients in which chemotherapy is not being considered or for those who would not be a candidate for chemotherapy, the panel is also not needed as it will not affect the treatment decision. 

<<< 2019 NCCN Annual Meeting


John H. Ward, MD, professor of Medicine, Huntsman Cancer Institute, University of Utah, discusses his preferences in multilane testing for patients with hormone receptor (HR)–positive, node-negative breast cancer.

For patients with HR-positive, node-negative breast cancer who would be considered for chemotherapy, the current recommendation is the 21-gene recurrence score as it is believed to be predictive of chemotherapy benefit. However, there are a couple of caveats, Ward explains. First, if a patient has already been tested with other assays, it is unnecessary to repeat testing with the 21-gene recurrence score. 

Ward says that there is no wrong choice when it comes to selecting an assay, but the 21-gene recurrence score is his preference. For patients in which chemotherapy is not being considered or for those who would not be a candidate for chemotherapy, the panel is also not needed as it will not affect the treatment decision. 

<<< 2019 NCCN Annual Meeting



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x